Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes
Brian R. Lindman(Washington University in St. Louis), Margaret M. Redfield(Unknown), Gregory D. Lewis(Brigham and Women's Hospital), Susan Joseph(University of Maryland, Baltimore), Víctor G. Dávila‐Román(Washington University in St. Louis), Steven E. McNulty, Douglas L. Mann(Washington University in St. Louis), Justin Vader, Lisa de las Fuentes(Washington University in St. Louis), Marc J. Semigran(Healthwise), Adrian F. Hernandez(Duke University Hospital)
Cited by 210
Related Papers
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
The Seattle Heart Failure Model
|Circulation|2006|2k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Medical Therapy for Heart Failure With Reduced Ejection Fraction
|Journal of the American College of Cardiology|2018|1.3k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k